ERBB2-low tumours are not a distinct biologic or prognostic subgroup from ERBB2-0 tumour breast cancer.
1. No significant difference in pCR, DFS, or OS was found for subgroup analysis of ERBB2-0 vs. ERBB2-low tumours 2. ...
Tag: ERBB2
FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
1. Overall survival rate at 12 months for the FOLFOX arm and ipilimumab arm was 70% and 57%, respectively. 2. ...